Express Scripts (ESRX) Upgraded to “Buy” by ValuEngine
Express Scripts (NASDAQ:ESRX) was upgraded by equities researchers at ValuEngine from a “hold” rating to a “buy” rating in a research note issued on Monday.
ESRX has been the subject of several other research reports. BidaskClub lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research report on Saturday, July 21st. Zacks Investment Research lowered shares of Express Scripts from a “hold” rating to a “sell” rating in a research report on Monday, July 23rd. William Blair upgraded shares of Express Scripts from a “market perform” rating to an “outperform” rating in a research report on Wednesday, August 1st. Robert W. Baird lowered shares of Express Scripts from an “outperform” rating to a “neutral” rating and set a $81.00 price target for the company. in a research report on Friday, July 20th. Finally, Royal Bank of Canada increased their price target on shares of Express Scripts to $94.00 and gave the company an “outperform” rating in a research report on Monday, August 27th. Three analysts have rated the stock with a sell rating, twelve have given a hold rating and five have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average target price of $85.58.
ESRX traded up $3.41 during trading on Monday, hitting $95.23. 10,161,700 shares of the company traded hands, compared to its average volume of 4,328,261. The firm has a market cap of $50.57 billion, a P/E ratio of 13.41, a PEG ratio of 1.13 and a beta of 1.00. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.59 and a current ratio of 0.71. Express Scripts has a one year low of $55.80 and a one year high of $96.45.
In other Express Scripts news, insider Christine Houston sold 12,898 shares of the company’s stock in a transaction dated Friday, August 10th. The shares were sold at an average price of $85.00, for a total transaction of $1,096,330.00. Following the sale, the insider now directly owns 110,908 shares of the company’s stock, valued at $9,427,180. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 0.79% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ESRX. FMR LLC lifted its holdings in shares of Express Scripts by 117.6% in the second quarter. FMR LLC now owns 1,419,840 shares of the company’s stock worth $109,626,000 after buying an additional 767,426 shares in the last quarter. HRT Financial LLC purchased a new stake in shares of Express Scripts in the second quarter worth about $312,000. Truvestments Capital LLC purchased a new stake in shares of Express Scripts in the second quarter worth about $246,000. WealthTrust Fairport LLC lifted its holdings in shares of Express Scripts by 2,259.9% in the second quarter. WealthTrust Fairport LLC now owns 7,882 shares of the company’s stock worth $609,000 after buying an additional 7,548 shares in the last quarter. Finally, BDO Wealth Advisors LLC lifted its holdings in shares of Express Scripts by 124.8% in the second quarter. BDO Wealth Advisors LLC now owns 1,639 shares of the company’s stock worth $127,000 after buying an additional 910 shares in the last quarter. 84.73% of the stock is currently owned by institutional investors and hedge funds.
About Express Scripts
Express Scripts Holding Company operates as a pharmacy benefit management (PBM) company in the United States and Canada. The company's PBM segment offers clinical solutions; and specialized pharmacy care, home delivery and specialty pharmacy, retail network pharmacy administration, benefit design consultation, drug utilization review, drug formulary management, public exchange, administration of group purchasing organization, and digital consumer health and drug information services.
Further Reading: Moving Average – How it Helps Investors in Stock Selection
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Express Scripts Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Express Scripts and related companies with MarketBeat.com's FREE daily email newsletter.